{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:29:42Z","timestamp":1788647382442,"version":"build-2803163510"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009060","name":"SIDACTION","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In individuals living with human immunodeficiency virus (HIV) and hepatitis B virus (HBV), widespread tenofovir (TDF)\u2013containing antiretroviral therapy (ART) has led to substantial decreases in HBV-DNA and HIV-RNA detection. However, the links between viral replication, liver fibrosis, and mortality remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 300 individuals living with HIV-HBV and undergoing ART were prospectively followed. Virological and clinical data were obtained at baseline and every 6\u201312 months. We quantified the associations between HBV-DNA, HIV-RNA, and liver fibrosis with risk of all-cause mortality using a joint longitudinal survival model. Viral detection, viral loads, and time-averaged cumulative viral loads of HIV and HBV were modeled as 3 separate exposures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During a median of 10.5 years (interquartile range, 4.0\u201314.6), the proportion undergoing TDF-containing ART (baseline = 18.7%, end of follow-up = 79.1%) and with undetectable HBV-DNA (baseline = 36.7%, end of follow-up = 94.8%) substantially increased. 42 participants died (incidence rate = 1.30\/100 person-years, 95% confidence interval [CI] = .96\u20131.76). The leading causes of death were non-AIDS\/non\u2013liver-related malignancies (28.6%), followed by liver-related (16.7%), AIDS-related (16.7%), and other (16.7%). All-cause mortality was associated with HBV-DNA viral load (adjusted hazards ratio [aHR] per log10 IU\/mL\u2005=\u20051.41, 95% CI\u2005=\u20051.04\u20131.93, P\u2005=\u2005.03) or time-averaged cumulative HBV-DNA (aHR per log10 copy-years\u2005=\u20051.37, 95% CI\u2005=\u20051.03\u20131.83, P\u2005=\u2005.03), but not undetectable HBV-DNA. Advanced liver fibrosis at baseline was also associated with increased mortality rates (aHR\u2005=\u20052.35, 95% CI\u2005=\u20051.16\u20134.76, P\u2005=\u2005.02). No significant association between HIV-RNA replication and mortality was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Concurrent and historical HBV replication and liver fibrosis are important drivers of all-cause mortality in largely TDF-treated individuals living with HIV-HBV, despite one-fifth of deaths being liver-related. HBV-DNA and liver fibrosis remain important prognostic indicators for this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciab594","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T11:35:03Z","timestamp":1625052903000},"page":"1012-1021","source":"Crossref","is-referenced-by-count":5,"title":["Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus\u2013Hepatitis B Virus\u2013Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort"],"prefix":"10.1093","volume":"74","author":[{"given":"Lorenza N C","family":"Dezanet","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, IPLESP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raisha","family":"Kassime","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, IPLESP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Miailhes","sequence":"additional","affiliation":[{"name":"H\u00f4pital de la Croix-Rousse, Hospices Civils de Lyon, Service de Maladies Infectieuses et Tropicales, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lascoux-Combe","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Saint-Louis, Service de Maladies Infectieuses, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Chas","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Tenon, Service de Maladies Infectieuses, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Maylin","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Saint-Louis, Laboratoire de Virologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Gabassi","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Saint-Louis, Laboratoire de Virologie, Paris, France"},{"name":"Universit\u00e9 de Paris, INSERM U944, Institut de Recherche Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayette","family":"Rougier","sequence":"additional","affiliation":[{"name":"Institut de M\u00e9decine et d\u2019Epid\u00e9miologie Appliqu\u00e9e, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Delaugerre","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Saint-Louis, Laboratoire de Virologie, Paris, France"},{"name":"Universit\u00e9 de Paris, INSERM U944, Institut de Recherche Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, IPLESP, Paris, France"},{"name":"APHP, H\u00f4pital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Boyd","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, IPLESP, Paris, France"},{"name":"APHP, H\u00f4pital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"2022032516092349600_CIT0001","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/cid\/ciz1170","article-title":"Global burden of hepatitis b infection in people living with human immunodeficiency virus: a systematic review and meta-analysis","volume":"71","author":"Leumi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022032516092349600_CIT0002","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/cid\/cis432","article-title":"Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection","volume":"55","author":"Falade-Nwulia","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022032516092349600_CIT0003","doi-asserted-by":"crossref","first-page":"946","DOI":"10.7326\/0003-4819-126-12-199706150-00003","article-title":"Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection","volume":"126","author":"Mellors","year":"1997","journal-title":"Ann Intern Med"},{"key":"2022032516092349600_CIT0004","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1097\/QAD.0b013e3283305a00","article-title":"Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements","volume":"23","author":"Antiretroviral Therapy Cohort Collaboration","year":"2009","journal-title":"AIDS"},{"key":"2022032516092349600_CIT0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","article-title":"Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration","volume":"384","author":"Smith","year":"2014","journal-title":"Lancet"},{"key":"2022032516092349600_CIT0006","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cgh.2007.06.015","article-title":"Risk and predictors of mortality associated with chronic hepatitis B infection","volume":"5","author":"Iloeje","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022032516092349600_CIT0007","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1093\/cid\/cit564","article-title":"Assessment of liver fibrosis by transient elastography in patients with HIV and hepatitis B virus coinfection in Nigeria","volume":"57","author":"Hawkins","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022032516092349600_CIT0008","first-page":"hep.31839","article-title":"Risk of hepatocellular carcinoma with hepatitis B viremia among HIV\/hepatitis B virus-coinfected persons in North America","author":"Kim","year":"2021","journal-title":"Hepatology"},{"key":"2022032516092349600_CIT0009","doi-asserted-by":"crossref","first-page":"ofaa226","DOI":"10.1093\/ofid\/ofaa226","article-title":"Decreased all-cause and liver-related mortality risk in HIV\/hepatitis B virus coinfection coinciding with the introduction of tenofovir-containing combination antiretroviral therapy","volume":"7","author":"van Welzen","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2022032516092349600_CIT0010","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"key":"2022032516092349600_CIT0011","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/hep.27182","article-title":"Persistent viremia in human immunodeficiency virus\/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications","volume":"60","author":"Boyd","year":"2014","journal-title":"Hepatology"},{"key":"2022032516092349600_CIT0012","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAI.0000000000002589","article-title":"Efficacy and safety of elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide as maintenance treatment in HIV\/HBV-coinfected patients","volume":"86","author":"Huang","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022032516092349600_CIT0013","volume-title":"Guidelines Version 10.1","author":"European AIDS Clinical Society","year":"2020"},{"key":"2022032516092349600_CIT0014","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/liv.14059","article-title":"Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection","volume":"39","author":"Tsai","year":"2019","journal-title":"Liver Int"},{"key":"2022032516092349600_CIT0015","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2019.03.032","article-title":"Incidence of hepatocellular carcinoma in HIV\/HBV-coinfected patients on tenofovir therapy: relevance for screening strategies","volume":"71","author":"Wandeler","year":"2019","journal-title":"J Hepatol"},{"key":"2022032516092349600_CIT0016","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/QAD.0000000000002073","article-title":"Hepatitis B virus coinfection is associated with high early mortality in HIV-infected Tanzanians on antiretroviral therapy","volume":"33","author":"Christian","year":"2019","journal-title":"AIDS"},{"key":"2022032516092349600_CIT0017","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/cid\/cix747","article-title":"Higher mortality despite early antiretroviral therapy in human immunodeficiency virus and hepatitis B virus (HBV)-coinfected patients with high HBV replication","volume":"66","author":"Kouam\u00e9","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022032516092349600_CIT0018","doi-asserted-by":"crossref","first-page":"e24731","DOI":"10.2196\/24731","article-title":"Subclinical and clinical outcomes in patients coinfected with HIV and chronic hepatitis B virus from clinical outpatient centers in France: protocol for an ambispective, longitudinal cohort study","volume":"10","author":"Boyd","year":"2021","journal-title":"JMIR Res Protoc"},{"key":"2022032516092349600_CIT0019","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11901-011-0096-0","article-title":"Noninvasive markers of hepatic fibrosis in chronic hepatitis B","volume":"10","author":"Poynard","year":"2011","journal-title":"Curr Hepat Rep"},{"key":"2022032516092349600_CIT0020","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jhep.2009.01.022","article-title":"Performance of 11 biomarkers for liver fibrosis assessment in HIV\/HBV co-infected patients","volume":"50","author":"Bottero","year":"2009","journal-title":"J Hepatol"},{"key":"2022032516092349600_CIT0021","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1097\/QAD.0000000000000795","article-title":"Rates and determinants of hepatitis B \u2018e\u2019 antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus","volume":"29","author":"Boyd","year":"2015","journal-title":"AIDS"},{"key":"2022032516092349600_CIT0022","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/1536867X20976311","article-title":"merlin\u2014a unified modeling framework for data analysis and methods development in Stata","volume":"20","author":"Crowther","year":"2020","journal-title":"Stata J"},{"key":"2022032516092349600_CIT0023","author":"Joint United Nations Programme on HIV\/AIDS","year":"2013"},{"key":"2022032516092349600_CIT0024","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/hiv.12367","article-title":"Chronic hepatitis B increases mortality and complexity among HIV-coinfected patients in South Africa: a cohort study","volume":"17","author":"Velen","year":"2016","journal-title":"HIV Med"},{"key":"2022032516092349600_CIT0025","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1097\/QAD.0b013e3283174636","article-title":"The role of HIV in serious diseases other than AIDS","volume":"22","author":"Phillips","year":"2008","journal-title":"AIDS"},{"key":"2022032516092349600_CIT0026","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1473-3099(06)70463-7","article-title":"Immunological recovery and antiretroviral therapy in HIV-1 infection","volume":"6","author":"Battegay","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"2022032516092349600_CIT0027","doi-asserted-by":"crossref","first-page":"e1001194","DOI":"10.1371\/journal.pmed.1001194","article-title":"CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE","volume":"9","author":"Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord","year":"2012","journal-title":"PLoS Med"},{"key":"2022032516092349600_CIT0028","doi-asserted-by":"crossref","first-page":"e0129550","DOI":"10.1371\/journal.pone.0129550","article-title":"Cancer-related causes of death among HIV-infected patients in France in 2010: evolution since 2000","volume":"10","author":"Vandenhende","year":"2015","journal-title":"PloS One"},{"key":"2022032516092349600_CIT0029","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/QAD.0000000000001574","article-title":"HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment","volume":"31","author":"Singh","year":"2017","journal-title":"AIDS"},{"key":"2022032516092349600_CIT0030","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/gutjnl-2015-310275","article-title":"Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)","volume":"66","author":"Nahon","year":"2017","journal-title":"Gut"},{"key":"2022032516092349600_CIT0031","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"2022032516092349600_CIT0032","doi-asserted-by":"crossref","first-page":"21426","DOI":"10.7448\/IAS.20.1.21426","article-title":"Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study","volume":"20","author":"Boyd","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"2022032516092349600_CIT0033","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pvr.2017.10.004","article-title":"Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions","volume":"4","author":"McCloskey","year":"2017","journal-title":"Papillomavirus Res"},{"key":"2022032516092349600_CIT0034","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1478-3231.2009.02147.x","article-title":"Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study","volume":"30","author":"Iloeje","year":"2010","journal-title":"Liver Int"},{"key":"2022032516092349600_CIT0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/M16-0240","article-title":"Chronic hepatitis B and C virus infection and risk for non-Hodgkin lymphoma in HIV-infected patients: a cohort study","volume":"166","author":"Wang","year":"2017","journal-title":"Ann Intern Med"},{"key":"2022032516092349600_CIT0036","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhep.2016.10.007","article-title":"Hepatitis delta-associated mortality in HIV\/HBV-coinfected patients","volume":"66","author":"B\u00e9guelin","year":"2017","journal-title":"J Hepatol"},{"key":"2022032516092349600_CIT0037","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1016\/S2352-3018(20)30301-5","article-title":"HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study","volume":"8","author":"Smit","year":"2021","journal-title":"Lancet HIV"},{"key":"2022032516092349600_CIT0038","doi-asserted-by":"crossref","first-page":"71.e9","DOI":"10.1016\/j.amjmed.2005.02.033","article-title":"Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B","volume":"119","author":"Arase","year":"2006","journal-title":"Am J Med"},{"key":"2022032516092349600_CIT0039","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jhep.2012.04.025","article-title":"Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population","volume":"57","author":"Poynard","year":"2012","journal-title":"J Hepatol"},{"key":"2022032516092349600_CIT0040","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/apt.12307","article-title":"Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus","volume":"37","author":"de L\u00e9dinghen","year":"2013","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab594\/39591872\/ciab594.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/74\/6\/1012\/42992423\/ciab594.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/74\/6\/1012\/42992423\/ciab594.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T16:28:51Z","timestamp":1648225731000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/74\/6\/1012\/6312684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,7,1]]},"published-print":{"date-parts":[[2022,3,23]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab594","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.13.21255432","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,15]]},"published":{"date-parts":[[2021,7,1]]}}}